DE60039453D1 - Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum - Google Patents

Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Info

Publication number
DE60039453D1
DE60039453D1 DE60039453T DE60039453T DE60039453D1 DE 60039453 D1 DE60039453 D1 DE 60039453D1 DE 60039453 T DE60039453 T DE 60039453T DE 60039453 T DE60039453 T DE 60039453T DE 60039453 D1 DE60039453 D1 DE 60039453D1
Authority
DE
Germany
Prior art keywords
pin1
cell growth
abnormal cell
metastasis
aggressiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60039453T
Other languages
English (en)
Inventor
Kun Ping Lu
Gerburg Wulf
Xiao Zhen Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Application granted granted Critical
Publication of DE60039453D1 publication Critical patent/DE60039453D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
DE60039453T 1999-11-29 2000-11-29 Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum Expired - Fee Related DE60039453D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16780099P 1999-11-29 1999-11-29
US25367600P 2000-11-28 2000-11-28
PCT/US2000/032560 WO2001038878A2 (en) 1999-11-29 2000-11-29 Pin1 as a marker for abnormal cell growth

Publications (1)

Publication Number Publication Date
DE60039453D1 true DE60039453D1 (de) 2008-08-21

Family

ID=26863487

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039453T Expired - Fee Related DE60039453D1 (de) 1999-11-29 2000-11-29 Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum

Country Status (7)

Country Link
EP (1) EP1234185B1 (de)
JP (1) JP2003515172A (de)
AT (1) ATE400814T1 (de)
CA (1) CA2392917C (de)
DE (1) DE60039453D1 (de)
HK (1) HK1051066A1 (de)
WO (1) WO2001038878A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532390A (ja) 2001-02-09 2004-10-21 ピンテックス ファーマシューティカルズ，インク． 前立腺癌のマーカとしてのｐｉｎ１
CA2437807A1 (en) * 2001-02-09 2002-08-22 Pintex Pharmaceuticals, Inc. Pin1 as marker for abnormal cell growth
EP1436624B1 (de) * 2001-09-12 2012-03-21 The Walter And Eliza Hall Institute Of Medical Research Diagnose- und behandlungsverfahren sowie dafür geeignete mittel
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
EP1572236A4 (de) * 2002-11-14 2007-01-03 Pintex Pharmaceuticals Inc Pin1-spiegel in normalem gewebe sowie in krebsgewebe
WO2022032179A1 (en) * 2020-08-07 2022-02-10 The Regents Of The University Of California Pin1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
ATE400814T1 (de) 2008-07-15
CA2392917C (en) 2007-05-01
EP1234185A2 (de) 2002-08-28
WO2001038878A2 (en) 2001-05-31
WO2001038878A3 (en) 2002-01-17
CA2392917A1 (en) 2001-05-31
JP2003515172A (ja) 2003-04-22
HK1051066A1 (zh) 2003-07-18
EP1234185B1 (de) 2008-07-09

Similar Documents

Publication Publication Date Title
WO2002065091A3 (en) Pin1 as marker for abnormal cell growth
MXPA03003281A (es) Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos.
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
WO2005032343A3 (en) Hedgehog signaling in prostate regeneration neoplasia and metastasis
NZ593388A (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
ATE389008T1 (de) Verfahren und vorrichtung zum züchten und/oder behandeln von zellen
WO2004083816A3 (en) Loss of heterozygosity of the dna markers in the 12q22-23 region
ATE511503T1 (de) Aryl- und heteroarylharnstoff-chk1-inhibitoren zur verwendung als radiosensibilisatoren und chemosensibilisatoren
DE69900841T2 (de) Durch enzymkatalyse erhaltene therapeutische substanzen.
GB2465940A (en) Neural tumor stem cells and methods of use thereof
ATE526029T1 (de) Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
ATE463092T1 (de) Busmodem für gebäude- und industrielle elektrische systeme
NO20014869L (no) Vevsinhibitorer av matriks metallproteinaser type-1 (TIMP-1) som en kreftmarkör
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
WO2007081790A3 (en) Methods for diagnosing and treating prostate cancer
AU2003302732A8 (en) Method for identifying risk of breast cancer and treatments thereof
DE60039453D1 (de) Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
WO2006052735A3 (en) Fibulin-3 and uses thereof
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
PT1529116E (pt) Métodos para o tratamento da demência com base no genótipo da apo e
ATE393917T1 (de) Identifikation von therapeutische verbindungen.
MX2008002123A (es) Metodos y composiciones para determinar un nivel de paraoxonasa de suero biologicamente activa.
ATE501252T1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee